Search

Displaying results 1661 - 1670 of 1901 in total
  1. Drug

    Sulisobenzone

    go.drugbank.com/drugs/DB11185
    Approved

    Sulisobenzone is approved by the FDA in concentrations of up to 10% and in Canada, is approved by Health Canada at the same concentrations [F38].

  2. Drug

    Vibrio cholerae CVD 103-HgR strain live antigen

    go.drugbank.com/drugs/DB14443
    ApprovedInvestigational

    [A244489] The FDA approved the cholera vaccine containing _Vibrio cholerae_ CVD 103-HgR strain live antigen under the brand name Vaxchora in June 2016, making it the first vaccine indicated for cholera

  3. Drug

    Ritlecitinib

    go.drugbank.com/drugs/DB14924
    ApprovedInvestigational

    In June 2023, it was approved by the FDA for the treatment of severe alopecia areata in adults and adolescents 12 years and older.[L47092,L47127] It was further approved by the EMA in September 2023.

  4. Drug

    Ferric derisomaltose

    go.drugbank.com/drugs/DB15617
    ApprovedInvestigational

    Ferric derisomaltose was developed by Pharmacosmos Therapeutics ad was granted FDA approval in January 2020.

  5. Drug

    Efanesoctocog alfa

    go.drugbank.com/drugs/DB16662
    ApprovedInvestigational

    [A257464,A257469] In February 2023, efanesoctocog alfa was approved by the FDA as a new class of factor VIII therapy for hemophilia A.[L45379,L45414]

  6. Drug

    Delandistrogene moxeparvovec

    go.drugbank.com/drugs/DB16802
    ApprovedInvestigational

    It was granted accelerated approval by the FDA on June 22, 2023, as the first gene therapy to treat Duchenne Muscular Dystrophy (DMD).

  7. Drug

    Tabelecleucel

    go.drugbank.com/drugs/DB17072
    ApprovedInvestigational

    [L43557] The FDA has granted tabelecleucel Breakthrough Therapy Designation for EBV-associated PTLD following allogeneic HCT.[L43562]

  8. Drug

    Chikungunya vaccine (live, attenuated)

    go.drugbank.com/drugs/DB18701
    ApprovedInvestigational

    [L48731] Chikungunya vaccine (live, attenuated) - marketed under the name Ixchiq - was approved by the FDA in November 2023, becoming the first and only vaccine indicated for the prevention of disease

  9. Drug

    Recombinant stabilized RSV A prefusion F antigen

    go.drugbank.com/drugs/DB18713
    ApprovedInvestigational

    [L48066] Abrysvo was first approved by the FDA in May 2023 for use in patients ≥60 years of age, and received subsequent approval in August 2023 for use in pregnant individuals for the protection of

  10. Drug

    Rimacalib

    go.drugbank.com/drugs/DB12571
    Investigational

    Rimacalib has been used in trials studying the treatment of Rheumatoid Arthritis (RA).